Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors.
Matoba T, Minohara K, Kawakita D, Takano G, Oguri K, Murashima A, Nakai K, Iwaki S, Tsuge H, Tanaka N, Imaizumi S, Hojo W, Matsumura A, Tsukamoto K, Esaki S, Iwasaki S.
Matoba T, et al. Among authors: esaki s.
Sci Rep. 2022 Aug 22;12(1):14319. doi: 10.1038/s41598-022-18611-z.
Sci Rep. 2022.
PMID: 35996017
Free PMC article.